Machine learning modeling to identify affinity improved biobetter anticancer drug trastuzumab and the insight of molecular recognition of trastuzumab towards its antigen HER2

References

• Balakrishnan, N., Gurunathan, B., & Surapaneni, K. M. (2020). Application of proteometric approach for identification of functional mutant sites to improve the binding affinity of anticancer biologic trastuzumab with its antigen human epidermal growth factor receptor 2. Journal of Molecular Recognition: JMR, 33(2), e2818–14. https://doi.org/10.1002/jmr.2818
   PubMed Web of Science ®Google Scholar
• Bazargani, Y. T., Boer, A., De, Schellens, J. H. M., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2015). Essential medicines for breast cancer in low and middle income countries. BMC Cancer, 15, 1–8. https://doi.org/10.1186/s12885-015-1583-4
   Google Scholar
• Bersell, K., Arab, S., Haring, B., & Kühn, B. (2009). Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell, 138(2), 257–270. https://doi.org/10.1016/j.cell.2009.04.060
   PubMed Web of Science ®Google Scholar
• Bonetta, R., & Valentino, G. (2020). Machine learning techniques for protein function prediction. Proteins, 88(3), 397–413. https://doi.org/10.1002/prot.25832
   PubMed Web of Science ®Google Scholar
• Caballero, J., Fernández, L., Garriga, M., Abreu, J. I., Collina, S., & Fernández, M. (2007). Proteometric study of ghrelin receptor function variations upon mutations using amino acid sequence autocorrelation vectors and genetic algorithm-based least square support vector machines. Journal of Molecular Graphics & Modelling, 26(1), 166–178. https://doi.org/10.1016/j.jmgm.2006.11.002
   PubMed Web of Science ®Google Scholar
• Cadet, F., Fontaine, N., Li, G., Sanchis, J., Ng Fuk Chong, M., Pandjaitan, R., Vetrivel, I., Offmann, B., & Reetz, M. T. (2018). A machine learning approach for reliable prediction of amino acid interactions and its application in the directed evolution of enantioselective enzymes. Scientific Reports, 8(1), 16757. https://doi.org/10.1038/s41598-018-35033-y
   PubMedGoogle Scholar
• Chang, C. C., & Lin, C. J. (2011). LIBSVM: A Library for support vector machines. ACM Transactions on Intelligent Systems and Technology, 2(3), 1–27. https://doi.org/10.1145/1961189.1961199
   Web of Science ®Google Scholar
• Cherkassky, V., & Ma, Y. (2004). Practical selection of SVM parameters and noise estimation for SVM regression. Neural Networks, 17(1), 113–126. https://doi.org/10.1016/S0893-6080(03)00169-2
   PubMed Web of Science ®Google Scholar
• Chothiav, C., & Tt, A. M. L. (1987). Canonical structures for the hypervariable regions of immunoglobulins. Journal of Molecular Biology, 196(4), 901–917. http://doi.org/10.1016/0022-2836(87)90412-8
   Google Scholar
• Fiszman, G. L., & Jasnis, A. (2011). Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. International Journal of Breast Cancer, 2011, 352182. https://doi.org/10.4061/2011/352182
   Google Scholar
• Frishman, D., & Argos, P. (1995). Knowledge-based protein secondary structure assignment. Proteins, 23(4), 566–579. https://doi.org/10.1002/prot.340230412
   PubMed Web of Science ®Google Scholar
• Gerstner, R. B., Carter, P., & Lowman, H. B. (2002). Sequence plasticity in the antigen-binding site of a therapeutic anti-Her2 antibody. Journal of Molecular Biology, 321(5), 851–862. https://doi.org/10.1016/S0022-2836(02)00677-0
   PubMed Web of Science ®Google Scholar
• Golbraikh, A., & Tropsha, A. (2002). Beware of q2!. Journal of Molecular Graphics and Modelling,20, 269–276. https://doi.org/10.1016/S1093-3263(01)00123-1
   Google Scholar
• Guex, N., Peitsch, M. C., & Schwede, T. (2009). Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis, 30(S1), S162–S173. https://doi.org/10.1002/elps.200900140
   PubMed Web of Science ®Google Scholar
• Harding, F. A., Akamatsu Yoshiko, Dubridge, R. B., & Powers, D. B. (2015). Anti-HER2 antibodies and their uses. U.S. Patent No.8,937,159 B2. Washington, DC: U.S. Patent and Trademark Office.
   Google Scholar
• Kabat, E. A., Wu, T. T., Perry, H. M., & Gottesman, K., F. C. (1991). Sequences of proteins of immunological interest (5th ed.). National Institutes of Health.
   Google Scholar
• Kelley, R. F., & O'Connell, M. P. (1993). Thermodynamic analysis of an antibody functional epitope. Biochemistry, 32(27), 6828–6835. https://doi.org/10.1021/bi00078a005
   PubMed Web of Science ®Google Scholar
• Li, B., Zhao, L., Wang, C., Guo, H., Wu, L., Zhang, X., Qian, W., Wang, H., & Guo, Y. (2010). The protein-protein interface evolution acts in a similar way to antibody affinity maturation. Journal of Biological Chemistry, 285(6), 3865–3871. https://doi.org/10.1074/jbc.M109.076547
   PubMed Web of Science ®Google Scholar
• Li, G., Guo, J., Shen, B.-Q., Yadav, D. B., Sliwkowski, M. X., Crocker, L. M., Lacap, J. A., & Phillips, G. D. L. (2018). Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Molecular Cancer Therapeutics, 17(7), 1441–1453. https://doi.org/10.1158/1535-7163.MCT-17-0296
   PubMed Web of Science ®Google Scholar
• Lippow, S. M., Wittrup, K. D., & Tidor, B. (2007). Computational design of antibody-affinity improvement beyond in vivo maturation. Nature Biotechnology, 25(10), 1171–1176. https://doi.org/10.1038/nbt1336
   PubMed Web of Science ®Google Scholar
• Lowe, D. C., Gerhardt, S., Ward, A., Hargreaves, D., Anderson, M., Ferraro, F., Pauptit, R. A., Pattison, D. V., Buchanan, C., Popovic, B., Finch, D. K., Wilkinson, T., Sleeman, M., Vaughan, T. J., & Mallinder, P. R. (2011). Engineering a high-affinity anti-IL-15 antibody: Crystal structure reveals an α-helix in VH CDR3 as Key component of paratope. Journal of Molecular Biology, 406(1), 160–175. https://doi.org/10.1016/j.jmb.2010.12.017
   PubMed Web of Science ®Google Scholar
• Luque-Cabal, M., García-Teijido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016). Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clinical Medicine Insights. Oncology, 10(Suppl 1), 21–30. https://doi.org/10.4137/CMO.S34537
   PubMedGoogle Scholar
• Ménard, S., Pupa, S. M., Campiglio, M., & Tagliabue, E. (2003). Biologic and therapeutic role of HER2 in cancer. Oncogene, 22(42), 6570–6578. https://doi.org/10.1038/sj.onc.1206779
   PubMed Web of Science ®Google Scholar
• Mitra, I., Saha, A., & Roy, K. (2010). Exploring quantitative structure-activity relationship studies of antioxidant phenolic compounds obtained from traditional Chinese medicinal plants. Molecular Simulation, 36(13), 1067–1079. https://doi.org/10.1080/08927022.2010.503326
   Web of Science ®Google Scholar
• Mohan, N., Jiang, J., Dokmanovic, M., & Wu, W. J. (2018). Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers. Antibody Therapeutics, 1(1), 13–17. https://doi.org/10.1093/abt/tby003
   PubMedGoogle Scholar
• Moon, S. K., Park, S. R., Park, A., Oh, H. M., Shin, H. J., Jeon, E. J., Kim, S., Park, H. J., Yeon, Y. J., & Yoo, Y. J. (2016). Substitution of heavy complementarity determining region 3 (CDR-H3) residues can synergistically enhance functional activity of antibody and its binding affinity to HER2 antigen. Molecules and Cells, 39(3), 217–228. https://doi.org/10.14348/molcells.2016.2235
   PubMed Web of Science ®Google Scholar
• Nixon, N. A., Hannouf, M. B., & Verma, S. (2018). The evolution of biosimilars in oncology, with a focus on trastuzumab. Current Oncology, 25, 171–179. http://doi.org/10.3747/co.25.3942
   Google Scholar
• Riccio, G., Coppola, C., Piscopo, G., Capasso, I., Maurea, C., Esposito, E., De Lorenzo, C., & Maurea, N. (2016). Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? Human Vaccines & Immunotherapeutics, 12(5), 1124–1131. https://doi.org/10.1080/21645515.2015.1125056
   PubMed Web of Science ®Google Scholar
• Roy, P. P., Paul, S., Mitra, I., & Roy, K. (2009). On two novel parameters for validation of predictive QSAR models. Molecules (Basel, Switzerland), 14(5), 1660–1701. https://doi.org/10.3390/molecules14051660
   PubMed Web of Science ®Google Scholar
• Shayanfar, A., & Shayanfar, S. (2014). Is regression through origin useful in external validation of QSAR models? European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences, 59(1), 31–35. https://doi.org/10.1016/j.ejps.2014.03.007
   PubMedGoogle Scholar
• Tan, A. R., & Swain, S. M. (2003). Ongoing adjuvant trials with trastuzumab in breast cancer. Seminars in Oncology, 30(5 Suppl 16), 54–64. https://doi.org/10.1053/j.seminoncol.2003.08.008
   PubMed Web of Science ®Google Scholar
• Team RC. (2013). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
   Google Scholar
• The PyMOL Molecular Graphics System, Version 2.0. (n.d.). Schrödinger, LLC.
   Google Scholar
• Trevino, V., & Falciani, F. (2006). GALGO: An R package for multivariate variable selection using genetic algorithms. Bioinformatics, 22(9), 1154–1156. https://doi.org/10.1093/bioinformatics/btl074
   Google Scholar
• Urquhart, L. (2018). Market watch: Top drugs and companies by sales in 2017. Nature Reviews Drug Discovery, 17(4), 232. https://doi.org/10.1038/nrd.2018.42
   PubMedGoogle Scholar
• Wells, J. A. (1990). Additivity of mutational effects in proteins. Biochemistry, 29(37), 8509–8517. https://doi.org/10.1021/bi00489a001
   PubMed Web of Science ®Google Scholar
• Wu, Z., Jennifer Kan, S. B., Lewis, R. D., Wittmann, B. J., & Arnold, F. H. (2019). Machine learning-assisted directed protein evolution with combinatorial libraries. Proceedings of the National Academy of Sciences of the United States of America, 116(18), 8852–8858. https://doi.org/10.1073/pnas.1901979116
   PubMed Web of Science ®Google Scholar
• Xiao, N., Cao, D.-S., Zhu, M.-F., & Xu, Q.-S. (2015). protr/ProtrWeb: R package and web server for generating various numerical representation schemes of protein sequences. Bioinformatics (Oxford, England), 31(11), 1857–1859. https://doi.org/10.1093/bioinformatics/btv042 25619996
   PubMed Web of Science ®Google Scholar